Literature DB >> 26309649

Serum copeptin as a new biomarker in the early diagnosis of decline in renal function of type 2 diabetes mellitus patients.

Wen Hu1, Yao-Jun Ni2, Li Ma1, Hai-Rong Hao1, Liang Chen1, Wei-Nan Yu1.   

Abstract

OBJECTIVE: This study aimed to investigate the correlation between serum copeptin and glomerular filtration rate (GFR) in type 2 diabetes mellitus (T2DM) patients and to investigate the role of serum copeptin in the diagnosis of early DN in T2DM patients.
METHODS: 120 T2DM inpatients were recruited and divided into 2 groups according to 24-h urine albumin excretion (UAE): normal UAE group (UAE<30 mg/24 h) and microalbuminuria group (30 mg/24 h≤UAE≤300 mg/24 h).
RESULTS: Decline in GFR was found in 6.1% of patients in normal UAE group and 26.4% in microalbuminuria group. However, serum copeptin was comparable between two groups. Serum copeptin was negatively related to GFR (r=-0.586, P<0.001). Multivariate logistic regression analysis showed, after adjustment for age and gender, the OR of copeptin, 24-h UAE was 1.234 (95% CI: 1.003-1.456) (P<0.05) and 1.068 (95% CI: 1.005-1.187) (P<0.05), respectively. Univariate analysis of ROC showed the sensitivity of copeptin and 24-h UAE was 78.9% and 63.2%, respectively and the specificity was 88.9% and 89.7%, respectively in the diagnosis of DN, but the area under ROC of copeptin in combination with 24-h UAE was 0.90 (95% CI: 0.82-0.99) with the sensitivity of 80.9% and specificity of 91.1%.
CONCLUSION: Serum copeptin is an independent risk factor of decline in renal function of T2DM patients. Copeptin in combination with 24-h UAE are helpful for the early diagnosis of DN. The causative relationship between serum copeptin and GFR is required to be further studied in long-term follow up.

Entities:  

Keywords:  Copeptin; glomerular filtration rate; urine albumin excretion

Year:  2015        PMID: 26309649      PMCID: PMC4537970     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  23 in total

1.  Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.

Authors:  Ravi Retnakaran; Carole A Cull; Kerensa I Thorne; Amanda I Adler; Rury R Holman
Journal:  Diabetes       Date:  2006-06       Impact factor: 9.461

2.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Authors:  Amanda I Adler; Richard J Stevens; Sue E Manley; Rudy W Bilous; Carole A Cull; Rury R Holman
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

3.  Glomerular structure in IDDM women with low glomerular filtration rate and normal urinary albumin excretion.

Authors:  P H Lane; M W Steffes; S M Mauer
Journal:  Diabetes       Date:  1992-05       Impact factor: 9.461

4.  Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system.

Authors:  Pascale Bardoux; Daniel Georges Bichet; Hélène Martin; Yves Gallois; Michel Marre; Marie-Françoise Arthus; Michèle Lonergan; Nicole Ruel; Nadine Bouby; Lise Bankir
Journal:  Nephrol Dial Transplant       Date:  2003-03       Impact factor: 5.992

Review 5.  Vasopressinergic regulation of the hypothalamic pituitary adrenal axis and stress adaptation.

Authors:  Simona Volpi; Cristina Rabadan-Diehl; Greti Aguilera
Journal:  Stress       Date:  2004-06       Impact factor: 3.493

6.  Plasma and platelet vasopressin in essential hypertension and congestive heart failure.

Authors:  J J Preibisz; J E Sealey; J H Laragh; R J Cody; B B Weksler
Journal:  Hypertension       Date:  1983 Mar-Apr       Impact factor: 10.190

7.  National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors:  Mary Jo Goolsby
Journal:  J Am Acad Nurse Pract       Date:  2002-06

8.  Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome.

Authors:  Umer Saleem; Mahyar Khaleghi; Nils G Morgenthaler; Andreas Bergmann; Joachim Struck; Thomas H Mosley; Iftikhar J Kullo
Journal:  J Clin Endocrinol Metab       Date:  2009-04-14       Impact factor: 5.958

9.  Nonalbuminuric renal insufficiency in type 2 diabetes.

Authors:  Richard J MacIsaac; Con Tsalamandris; Sianna Panagiotopoulos; Trudy J Smith; Karen J McNeil; George Jerums
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

10.  Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria.

Authors:  Gilberto Velho; Nadine Bouby; Samy Hadjadj; Nadia Matallah; Kamel Mohammedi; Frédéric Fumeron; Louis Potier; Naïma Bellili-Munoz; Christopher Taveau; François Alhenc-Gelas; Lise Bankir; Michel Marre; Ronan Roussel
Journal:  Diabetes Care       Date:  2013-07-17       Impact factor: 19.112

View more
  1 in total

Review 1.  Pathophysiology of copeptin in kidney disease and hypertension.

Authors:  Baris Afsar
Journal:  Clin Hypertens       Date:  2017-06-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.